• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 and Women’s Health

Prospective Data: COVID-19 Vaccinations Rates and Associated Pregnancy Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Stock et al. (Nature Medicine, 2022) describe COVID-19 vaccine uptake and SARS-CoV-2 infection in pregnant women in Scotland

METHODS:

  • National, prospective dynamic pregnancy cohort
    • All ongoing and completed pregnancies in Scotland, United Kingdom, since March 1, 2020 
  • Population
    • All women who were pregnant on, or became pregnant after, March 1, 2020
  • Exposures
    • Infection in pregnancy
      • Infection at any point from the estimated date of conception to the date the pregnancy ends
    • Vaccination status
      • Unvaccinated
      • Partially vaccinated
      • Fully vaccinated
  • Primary outcomes
    • Uptake and coverage of COVID-19 vaccination
    • COVID-19 outcomes in pregnant women

RESULTS:

  • 18,457 vaccinated pregnant women
  • Vaccine coverage was substantially lower in pregnant women than in the general population of reproductive aged women
    • Pregnant women: 32.3%
    • All reproductive aged women: 77.4%
  • Extended perinatal mortality rate for women who gave birth within 28 days of a COVID-19 diagnosis
    • 22.6 per 1,000 births (95% CI, 12.9 to 38.5)
    • Pandemic background rate among uninfected women: 5.6 per 1,000 births (95% CI, 5.1 to 6.2)
  • The majority of adverse pregnancy outcomes occurred in women who were unvaccinated
    • SARS-CoV-2 infection
      • 77.4% occurred in unvaccinated (95% CI, 76.2 to 78.6)
    • SARS-CoV-2 infection associated hospital admission
      • 90.9% occurred in unvaccinated (95% CI, 88.7 to 92.7)
    • SARS-CoV-2 infection associated critical care admission
      • 98% occurred in unvaccinated (95% CI, 92.5 to 99.7)
    • Infant deaths
      • All occurred in unvaccinated women

CONCLUSION:

  • Most adverse pregnancy outcomes during the study period occurred in pregnant women who were unvaccinated and experienced SARS-CoV-2 infection during pregnancy
  • The authors state

Our data support the importance of women being vaccinated in pregnancy to prevent adverse outcomes associated with COVID-19

For extended perinatal mortality, for example, we find substantially elevated rates among women who had SARS-CoV-2 within 28 d of birth; conversely, for women who had COVID-19 vaccination, extended perinatal morality rates were similar to background rates and among women with no confirmed SARS-CoV-2

Learn More – Primary Sources:

SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 and Women’s Health Posts
Next >

Related ObG Topics:

mRNA COVID-19 Vaccine Safety in Pregnant Women
Vaccines in Pregnant and Lactating Women: Is Immune Response Similar to that of Non-Pregnant Patients?
COVID-19 Vaccination and Miscarriage: Another Study Finds No Link

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site